SABCS 2022

Conference Coverage

SABCS 2022: Trials Show Improved Outcomes in HR+, HER2- Breast Cancer

The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.

Platinum Chemo “Should Be Standard” for Younger Patients With TNBC

Adding carboplatin to standard neoadjuvant chemotherapy improved outcomes in younger patients with triple-negative breast cancer.

Cemiplimab Plus REGN3767 and Chemo Shows Promise for HER2- Breast Cancer

Combination cemiplimab, REGN3767, and chemotherapy appears effective in triple-negative breast cancer and HR+, HER2- breast cancer.

Germline PVs in BRCA1/2, CHEK2 Linked to Higher Risk of Contralateral Breast Cancer

Patients with germline pathogenic variants in BRCA1, BRCA2, and CHEK2 have an increased risk of contralateral breast cancer.

Interrupting ET for Pregnancy Does Not Seem to Affect Short-Term Outcomes of Breast Cancer

Interrupting endocrine therapy so patients with breast cancer can attempt pregnancy does not appear to impact short-term disease outcomes.

Palbociclib Does Not Improve PFS After Progression on CDK4/6 Inhibitors, ET

Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast cancer.

Camizestrant Improves PFS vs Fulvestrant in ER+/HER2- Advanced Breast Cancer

Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.

Trastuzumab Deruxtecan Elicits Responses in HER2-Low Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan appears active in patients with HER2-low, hormone receptor-positive, early breast cancer.

Capivasertib Improves PFS in AI-Resistant, HR+/HER2– Advanced Breast Cancer

Adding capivasertib to treatment with fulvestrant improved progression-free survival in aromatase inhibitor-resistant, HR+, HER2- advanced breast cancer.

Duration of Prior CDK4/6 Inhibitor Treatment Tied to PFS With Elacestrant

The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.

Ribociclib Plus ET Outperforms Chemo in HR+/HER2− Advanced Breast Cancer

Ribociclib plus endocrine therapy prolongs progression-free survival when compared with chemotherapy in HR+/ HER2− advanced breast cancer.

Older Patients With Metastatic Breast Cancer Often Do Not Receive First-Line Systemic Therapy

A retrospective study revealed characteristics of patients with metastatic breast cancer who are not likely to receive first-line systemic therapy.

Breast Cancer Index Predicts Response to Ovarian Function Suppression

The Breast Cancer Index can predict benefit from ovarian function suppression in premenopausal patients with HR+, early-stage breast cancer.

T-DXd Improves Survival vs T-DM1 in HER2+ Advanced Breast Cancer

Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

TAILORx Update Confirms Intermediate-Risk Breast Cancer Patients Can Forgo Chemotherapy

Patients with HR+/HER2-, intermediate-risk, early breast cancer can forgo chemotherapy without increasing their risk of late recurrence, updated data suggest.

Abemaciclib Provides Long-Term Benefits in HR+, HER2- Breast Cancer

Adding abemaciclib to adjuvant endocrine therapy can provide long-term benefits for patients with high-risk, HR+, HER2- early breast cancer, updated data suggest.

Trastuzumab Deruxtecan Improves PFS and OS in HER2+ Advanced Breast Cancer

Trastuzumab deruxtecan improves outcomes vs physician’s choice of treatment in patients with previously treated, HER2+, advanced breast cancer.

Adding Everolimus to Adjuvant ET Does Not Improve Survival in High-Risk HR+/HER2- Breast Cancer

Adding everolimus to adjuvant endocrine therapy does not improve survival for patients with HR+, HER2- breast cancer.

Adding Chemo to Endocrine Therapy Increases Cognitive Impairment in HR+, HER2- Breast Cancer

Adding chemotherapy to endocrine therapy leads to greater cognitive impairment in postmenopausal patients with breast cancer, a study suggests.

DFS Improved With AIs vs Tamoxifen in HR+, HER2- Early Breast Cancer

Aromatase inhibitors improved disease-free survival when compared with tamoxifen in HR+, HER2- early breast cancer, regardless of menopausal status.